Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repetitive CHMI for Malaria Immunity
NCT03014258Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2017
- Primary completion
- Jul 2019
- Countries
- 1
01
Overview
Phase 1, open-label trial in malaria (5 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Percentage of subjects testing positive for parasites, Percentage of subjects with positive malaria smear and 1 more. Started Jun 2017; status: completed.
02
Conditions
malaria
Beyond the preview
Go deeper on NCT03014258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03014258.